420 filings
Page 3 of 21
8-K
qnui7vwd83bgl2
4 May 23
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
4:02pm
EFFECT
syx2131b44h
3 May 23
Notice of effectiveness
12:15am
CORRESP
45cvk50n4ous9y3i05
28 Apr 23
Correspondence with SEC
12:00am
EFFECT
o6mqxi8t9063fr
27 Apr 23
Notice of effectiveness
12:00am
POS AM
1ppi3efg5dav jo8ue
25 Apr 23
Prospectus update (post-effective amendment)
4:09pm
8-K
jckr9fc
21 Apr 23
Termination of a Material Definitive Agreement
4:04pm
UPLOAD
uxvzqak2tgu
13 Apr 23
Letter from SEC
12:00am
8-K
hj3fo2sb u9fgsi57i
29 Mar 23
Avalo Reports 2022 Financial Results and Provides Business Updates
7:32am
8-K
s1zzuohy1bna66fyliaw
13 Mar 23
Regulation FD Disclosure
8:06am
8-K
uz5to sdwsp4
3 Feb 23
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
4:04pm
424B5
2qw1tdbx85r4i n6a5
3 Feb 23
Prospectus supplement for primary offering
4:02pm
424B5
21qhc
2 Feb 23
Prospectus supplement for primary offering
4:03pm
8-K
povwfpnatk ll52059lr
17 Jan 23
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
4:09pm
8-K
1e1ef8w5idydyv7f3g7
14 Nov 22
Completion of Acquisition or Disposition of Assets
7:00am
S-8
k356h7
7 Nov 22
Registration of securities for employees
7:43am
8-K
1wa1fklegm
7 Nov 22
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
7:31am